ISSUE – Feb. 19 | Theranos might be on life support

It probably comes as no surprise: Theranos, the blood testing technology company once worth billions, is struggling to survive. A new report from The Wall Street Journal says the company had just $200 million cash on hand left at the end of 2016 — a quarter of its $800 million in total funding.

According to the Journal’s investor sources, Theranos disclosed that number on a conference call in January in which the company also admitted it hadn’t made any material revenue in both 2015 and 2016 [ Tech Crunch ]